Evidence from randomized trials have also demonstrated the effect of PSA screening in mortality reduction of prostate cancer, by 20% at 16 year of follow-up from ERSPS (49) and by 35% at 18 year of follow-up from Göteborg screening trial (50). This evidence concerns the gene KLK3 and prostate carcinoma.